Skye Bioscience, Inc. 10-K

Item 9A. Controls and Procedures . Evaluation of Disclosure Controls and Procedures We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. Based upon their evaluation of those controls and procedures performed as of the end of the period covered by this report, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective. Management’s Annual Report on Internal Control over Financial Reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, a company’s principal executive and principal financial officers and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") and includes those policies and procedures that: • pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and dispositions of the Company; • provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with GAAP, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the Company; and • provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Our management, with the supervision and participation of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December 31, 2024, based on criteria for effective internal control over financial reporting set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework - 2013 (COSO 2013 Framework). Based on their assessment, our management concluded that, as of December 31, 2024, our internal control over financial reporting was effective. 77 As we are a smaller reporting company, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting. Changes in Internal Control over Financial Reporting There was no change in our internal control over financial reporting during the fourth quarter ended December 31, 2024 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Item 9B. Other Information. 2025 Annual Meeting of Stockholders We currently intend to hold our 2025 annual meeting of stockholders (the “2025 Annual Meeting”) on June 6, 2025. Our Amended and Restated Bylaws (“Bylaws”) provide notice procedures for stockholders to nominate a person as a director and to propose business to be considered by stockholders at an annual meeting of stockholders. A stockholder’s notice must be delivered in writing to the Secretary of the Company at Skye Bioscience, Inc., 11250 El Camino Real, Suite 100, San Diego, CA 92130 and must set forth, as to each matter the stockholder proposes to bring before the annual meeting, the information required by our Bylaws. In order to be timely, a stockholder’s notice must be delivered to the Secretary of the Company not later than the close of business on the 90th day nor earlier than the opening of business on the 120th day prior to the first anniversary of the date for the preceding year’s annual meeting of stockholders; provided that in the event that the date of the annual meeting is more than 30 days before or more than 70 days after such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the close of business on the 120th day prior to the date of such annual meeting and not later than the close of business on the later of the 90th day prior to the date of such annual meeting or the 10th day following the day on which public announcement (as defined in the Bylaws) of the date of such annual meeting is first made by the Company. Because we did not hold an annual meeting of stockholders in the year ended December 31, 2024 (“2024 Annual Meeting”), in order to be timely, a stockholder’s notice must be delivered, as set forth above, not earlier than the close of business on February 6, 2025 and not later than the close of business on March 30, 2025. Stockholders who intend to solicit proxies in support of director nominees, other than the Company’s nominees, must also provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act. In addition, because we did not hold a 2024 Annual Meeting, stockholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act and intended to be presented at the 2025 Annual Meeting must be delivered, as set forth above, a reasonable time before the Company begins to print and send its proxy materials for the 2025 Annual Meeting in order to be considered for inclusion in the Company’s proxy materials for that meeting. For purposes of the foregoing, we have determined that March 30, 2025 is a reasonable time before the Company intends to begin printing and sending its proxy materials for the 2025 Annual Meeting. Director and Officer Trading Arrangements On December 17, 2024 , each of 5AM Partners VII, LLC (the general partner of 5AM Ventures VII, L.P.) and 5AM Partners II, LLC (the general partner of 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P.) entered into a Stock Sale Plan (the " 10b5-1 Plan ") with Piper Sandler & Co. ("Piper Sandler"), pursuant to which Piper Sandler is authorized to sell up to an aggregate of 2,000,000 shares of Common Stock on behalf of 5AM Partners VII, LLC and 5AM Partners II, LLC during the period beginning on the later of (i) March 17, 2025 and (ii) two business days after filing the Issuer's Form 10-K for the year ending December 31 (but no later than April 16, 2025), and ending December 17, 2025 , subject to earlier termination in accordance with the terms of the 10b5-1 Plan and applicable laws, rules and regulations. Transactions under the 10b5-1 Plan will be subject to certain price restrictions and other restrictions under the terms of the 10b5-1 Plan. The 10b5-1 Plan is intended to comply with the requirements of Rule 10b5-1(c) promulgated under the Act. Andrew Schwab, a member of the Board of Directors of the Company, is a managing member of each of 5AM Partners VII, LLC and 5AM Partners II, LLC and may be deemed to share voting and investment power over the shares held by 5AM Partners VII, LLC and 5AM Partners II, LLC. Mr. Schwab disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Except as set forth above, none of our directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the fourth quarter of 2024. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. Not applicable. 78 PART III Item 10. Directors, Executive Officers and Corporate Governance . Information required by this item will be contained in our definitive Proxy Statement to be filed with the Securities and Exchange Commission on Schedule 14A in connection with our 2025 Annual Meeting (the "Proxy Statement"), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2024, under the headings “Executive Officers,” “Election of Directors,” “Information Regarding the Board of Directors and Corporate Governance,” and “Delinquent Section 16(a) Reports,” and is incorporated herein by reference. Item 11. Executive Compensation . The information required by this item regarding executive compensation is incorporated by reference to the information set forth in the section titled “Executive Compensation” in our Proxy Statement. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference to the information set forth in the section titled “Security Ownership of Certain Beneficial Owners and Management” in our Proxy Statement. The information required by Item 201(d) of Regulation S-K is incorporated by reference to the information set forth in the section titled “Executive Compensation” in our Proxy Statement. Item 13. Certain Relationships and Related Transactions, and Director Independence . The information required by this item regarding certain relationships and related transactions and director independence is incorporated by reference to the information set forth in the sections titled “Transactions with Related Parties” and “Election of Directors – Independence of the Board of Directors,” respectively, in our Proxy Statement. Item 14. Principal Accounting Fees and Services . The information required by this item regarding principal accountant fees and services is incorporated by reference to the information set forth in the section titled “Principal Accountant Fees and Services” in our Proxy Statement. 79 PART IV Item 15. Exhibits, Financial Statement Schedules . Financial Statements. The following consolidated financial statements of Skye Bioscience, Inc., together with the report thereon of Marcum LLP, an independent registered public accounting firm (PCAOB Firm No. 688 ), are included in this Annual Report. 80 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page No. Reports of Independent Registered Public Accounting Firm (PCAOB ID 688 ) F- 2 Consolidated Balance Sheets as of December 31, 2024 and 2023 F- 3 Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F- 4 Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F- 5 Consolidated Statements of Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023 F- 7 Notes to the C onsolidated F inancial S tatements F- 8 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and Board of Directors of Skye Bioscience, Inc. and Subsidiaries Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Skye Bioscience, Inc. and Subsidiaries (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, based on our audits, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America. Basis for Opinion These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. Critical Audit Matters Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters. /s/ Marcum LLP Marcum LLP We have served as the Company's auditor since 2022. Morristown, NJ March 20, 2025 F-2 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December 31 ASSETS 2024 2023 Current assets Cash and cash equivalents $ 68,415,741 $ 1,256,453 Restricted cash — 9,080,202 Prepaid expenses 201,962 194,259 Other current assets 2,209,544 1,119,929 Total current assets 70,827,247 11,650,843 Property and equipment, net 1,432,752 43,276 Operating lease right-of-use asset 449,864 237,983 Other assets 53,910 8,309 Total assets $ 72,763,773 $ 11,940,411 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities Accounts payable $ 569,252 $ 956,754 Accrued interest - related party — 126,027 Accrued interest - legal contingency — 234,750 Accrued payroll liabilities 1,114,255 888,381 Other current liabilities 654,201 991,805 Estimate for accrued legal contingencies and related expenses 1,818,751 6,259,246 Convertible note - related party, net of discount — 4,371,998 Operating lease liability, current portion 182,428 72,038 Total current liabilities 4,338,887 13,900,999 Non-current liabilities Operating lease liability, net of current portion 273,162 171,230 Total liabilities 4,612,049 14,072,229 Commitments and contingencies (Note 11) Stockholders’ equity (deficit) Preferred stock, $ 0.001 par value; 200,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023 — — Common stock, $ 0.001 par value; 100,000,000 shares authorized at December 31, 2024 and 2023, respectively; 30,974,559 and 12,349,243 shares issued and outstanding at December 31, 2024 and 2023, respectively 30,975 12,349 Additional paid-in-capital 199,070,421 102,238,382 Accumulated deficit ( 130,949,672 ) ( 104,382,549 ) Total stockholders’ equity (deficit) 68,151,724 ( 2,131,818 ) Total liabilities and stockholders’ equity (deficit) $ 72,763,773 $ 11,940,411 See accompanying notes to the consolidated financial statements. F-3 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS Year Ended December 31 2024 2023 Operating expenses Research and development $ 18,701,694 $ 5,819,461 Cost to acquire IPR&D asset — 21,215,214 General and administrative 17,725,741 7,852,340 Change in estimate for legal contingency ( 4,234,717 ) ( 151,842 ) Income from insurance recovery ( 2,000,000 ) — Total operating expenses 30,192,718 34,735,173 Operating loss ( 30,192,718 ) ( 34,735,173 ) Other (income) expense Interest expense 749,308 906,270 Interest income ( 3,028,762 ) ( 99,974 ) Wind-down costs — 409,347 (Gain) loss from asset sale ( 1,358,412 ) 307,086 Debt conversion inducement expense — 1,383,285 Other expense (income) 2,200 ( 3 ) Total other (income) expense, net ( 3,635,666 ) 2,906,011 Loss before income taxes ( 26,557,052 ) ( 37,641,184 ) Provision for income taxes 10,071 3,600 Net loss $ ( 26,567,123 ) $ ( 37,644,784 ) Loss per common share Basic $ ( 0.73 ) $ ( 5.37 ) Diluted $ ( 0.73 ) $ ( 5.37 ) Weighted average shares of common stock outstanding used to compute loss per share: Basic 36,486,519 7,006,038 Diluted 36,486,519 7,006,038 See accompanying notes to the consolidated financial statements. F-4 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31 2024 2023 Cash flows from operating activities: Net loss $ ( 26,567,123 ) $ ( 37,644,784 ) Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities: Write-down of vendor deposits 325,610 — Depreciation and amortization 298,640 124,251 Net loss (gain) on disposal of asset 10,794 ( 4,080 ) Stock-based compensation expense 8,317,480 987,510 Change in fair value of derivative liability — ( 3 ) Amortization of debt discount 599,006 329,890 Change in estimate for legal contingencies ( 4,234,717 ) ( 151,842 ) (Gain) loss from divestiture of asset ( 1,358,412 ) 307,086 Debt conversion inducement expense — 1,383,285 Accrued interest conversion expense — 15,952 Cost to acquire IPR&D asset — 21,215,214 Foreign currency remeasurement gain — ( 45,350 ) Changes in assets and liabilities: Prepaid expenses ( 7,703 ) 795,232 Other assets ( 45,601 ) — Other current assets ( 1,415,225 ) ( 488,790 ) Accounts payable ( 586,533 ) ( 576,384 ) Accounts payable – related parties — ( 124,901 ) Accrued interest – related party ( 126,027 ) 126,027 Accrued interest - legal contingency ( 234,750 ) 234,750 Accrued payroll liabilities 225,874 230,647 Other current liabilities ( 344,351 ) ( 493,472 ) Other current liabilities - related parties — ( 95,850 ) Operating lease liability ( 94,442 ) ( 76,566 ) Net cash, cash equivalents and restricted cash used in operating activities ( 25,237,480 ) ( 13,952,178 ) Cash flows from investing activities: Proceeds from asset sales, net of legal expenses 1,358,412 5,532,266 Purchases of property and equipment ( 1,604,027 ) ( 12,550 ) Cash acquired in asset acquisition — 1,076,740 Net cash cash equivalents and restricted cash (used in) provided by investing activities ( 245,615 ) 6,596,456 Cash flows from financing activities: Proceeds from PIPE financing, net of $ 6,434,447 and $ 265,053 issuance costs, respectively 83,556,563 11,734,947 Proceeds from convertible note - related party — 4,973,684 Financing costs allocated to warrants issued with convertible debt — ( 6,026 ) Proceeds from options exercises 5,618 — Repayment of loan payable — ( 259,335 ) Net cash, and cash equivalents and restricted cash provided by financing activities 83,562,181 16,443,270 Net increase in cash and cash equivalent and restricted cash 58,079,086 9,087,548 Cash, cash equivalents and restricted cash , beginning of year $ 10,336,655 $ 1,249,107 Cash, cash equivalents and restricted cash, end of year $ 68,415,741 $ 10,336,655 Supplemental disclosures of cash-flow information: Reconciliation of cash and cash equivalent and restricted cash: F-5 Cash and cash equivalent $ 68,415,741 $ 1,256,453 Restricted cash — 9,080,202 Total cash and cash equivalent and restricted cash shown in the consolidated statements of cash flows $ 68,415,741 $ 10,336,655 Cash paid during the year for: Interest $ 433,336 $ 198,352 Income taxes 5,200 3,600 Supplemental disclosures of non-cash financing activities: Financing of insurance premium $ — $ 203,884 Common stock warrant exercises — 282,906 Conversion of multi-draw credit agreement — 1,565,470 Conversion of accrued interest due to related party — 31,766 Right of use asset obtained in exchange for operating lease liabilities 306,764 241,134 Stock issued for assets — 20,532,846 Conversion of convertible note - related party 4,971,004 — See accompanying notes to the consolidated financial statements. F-6 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY Stockholders' Deficit Common Stock Additional Paid-In Capital Accumulated Deficit Total Stockholders' (Deficit) Equity Shares Amounts Balance, December 31, 2022 3,654,119 $ 3,654 $ 63,726,057 $ ( 66,737,765 ) $ ( 3,008,054 ) Stock-based compensation expense 10,333 10 987,500 — 987,510 Exercise of common stock warrants 66,566 67 282,839 — 282,906 Conversion of multi-draw credit agreement - related party and accrued interest 165,517 166 2,980,355 — 2,980,521 Common stock issued in acquisition of IPR&D asset 5,436,378 5,436 21,604,150 — 21,609,586 PIPE Financing, net of equity issuance costs $ 265,053 2,989,981 2,990 11,731,957 — 11,734,947 Warrants issued with convertible note — — 925,550 — 925,550 Common stock issued for fractional share adjustment in reverse stock split 26,349 26 ( 26 ) — — Net loss for the year ended December 31, 2023 — — — ( 37,644,784 ) ( 37,644,784 ) Balance, December 31, 2023 12,349,243 $ 12,349 $ 102,238,382 $ ( 104,382,549 ) $ ( 2,131,818 ) Issuance of Common Stock and Warrants, net of equity issuance costs $ 6,434,447 15,713,664 15,714 83,540,849 — 83,556,563 Stock-based compensation expense 639,664 640 8,316,840 — 8,317,480 Exercise of stock options 1,605 2 5,616 — 5,618 Exercise of pre-funded warrants 1,301,410 1,301 ( 1,301 ) — — Conversion of convertible note - related Party 968,973 969 4,970,035 — 4,971,004 Net loss for the year ended December 31, 2024 — — — ( 26,567,123 ) ( 26,567,123 ) Balance, December 31, 2024 30,974,559 $ 30,975 $ 199,070,421 $ ( 130,949,672 ) $ 68,151,724 See accompanying notes to the consolidated financial statements. F-7 SKYE BIOSCIENCE, INC. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. Nature of Operations and Business Activities Nature of Operations Skye Bioscience, Inc. (the “Company” or “Skye”) was incorporated in Nevada on March 16, 2011. The Company is a clinical stage biopharmaceutical company developing next-generation molecules that modulate G protein-coupled receptors to treat obesity, overweight and metabolic diseases. On August 18, 2023, the Company completed a strategic transaction to acquire a clinical asset pursuant to an Agreement and Plan of Merger and Reorganization, dated as of August 15, 2023 (the "BRB Merger Agreement"), by and among the Company, Bird Rock Bio, Inc. and Aquila Merger Sub, Inc., pursuant to which Aquila Merger Sub, Inc. merged with and into Bird Rock Bio, Inc. with Bird Rock Bio, Inc. surviving as a wholly owned subsidiary of the Company (the “BRB Acquisition”). In connection with the BRB Acquisition, Bird Rock Bio, Inc. changed its name from Bird Rock Bio, Inc. to Bird Rock Bio Sub, Inc. ("BRB"). In the BRB Acquisition, the Company issued to certain former stockholders of BRB an aggregate of 5,436,378 shares of the common stock of the Company, valued at $ 21,609,586 (See Note 3 to the accompanying consolidated financial statements). As of December 31, 2024, the Company has devoted substantially all its efforts to securing its product pipeline, carrying out its own research and development, preparing for and conducting clinical trials, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so. Impact of Geopolitical and Macroeconomic Factors It is possible that the Company may encounter supply chain issues related to global economic and political conditions such as a lack of production or laboratory resources, pandemics or cyberattacks that could cause business disruptions and clinical trial delays which will need to be managed in the future. There may also be significant uncertainty resulting from the impact of other geopolitical and macroeconomic factors, including global pandemics, inflation, supply chain issues, rising interest rates, future bank failures, increased geopolitical tensions between the U.S. and China and the impact of the Russia/Ukraine conflict and the Israel-Hamas war. 2. Summary of Significant Accounting Policies Basis of Presentation The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates. Certain reclassifications have been made to the amounts in prior periods to conform to the current period’s presentation, primarily the separate classification of prepaid expenses and other current assets on the Company's consolidated balance sheet, and consolidated statement of cash flows, the classification of legal costs and accruals as part of the estimate for accrual for legal contingencies and related expenses on the Company's consolidated balance sheet, and consolidated statement of cash flows and change in fair value of derivative liability and interest expense on the consolidated statement of operations. Such reclassifications did not have a material impact on the consolidated financial statements. Assets Held for Sale On November 10, 2022, the Company completed the acquisition of Emerald Health Therapeutics ("EHT") (the "EHT Acquisition"). At the time of the EHT Acquisition there were arrangements in place to sell the acquired assets and liabilities that comprised two of EHT's subsidiaries, Emerald Health Therapeutics Canada, Inc. ("EHTC") and Verdélite Sciences, Inc. ("VDL"). As a result, EHTC and VDL were considered held for sale since the EHT Acquisition and the Company has classified the associated assets of VDL as held for sale on the Consolidated Balance Sheets and the period costs related to both EHTC and VDL have been presented as wind-down costs in the Consolidated Statements of Operations. EHTC was divested on December 28, 2022, and VDL was divested on February 9, 2023 (see Note 3 to the accompanying consolidated financial statements). Assets meeting the held-for-sale criteria are classified as held for sale on the Consolidated Balance Sheets in subsequent periods until sold. F-8 Assets that meet the held-for-sale criteria are held for sale and reported at the lower of their carrying value or their fair value, less estimated costs to sell. Changes in fair value are recorded as a gain or loss in the results of operations but not to exceed the original carrying value. Due to the asset acquisition accounting on the date of the EHT Acquisition, Avalite Sciences, Inc. ("AVI") had no initial carrying value. Refer to Note 3 of the accompanying consolidated financial statements for further information. Derecognition of Nonfinancial Assets The Company generally accounts for sales of nonfinancial assets that are outside the scope of our ordinary activities under ASC 610-20, Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets. Pursuant to ASC 610-20, the Company applies the guidance in ASC 606 to determine if a contract exists, identify the distinct nonfinancial assets, and determine when control transfers and, therefore, when to derecognize the nonfinancial asset. Additionally, the Company applies the measurement principles of ASC 606 to determine the amount of consideration, if any, to include in the calculation of the gain or loss for the sale of the nonfinancial asset. Refer to Note 3 for further information. Principles of Consolidation The accompanying consolidated financial statements as of December 31, 2024, include the accounts of the Company and its wholly owned subsidiaries SKYE Bioscience Australia, EHT, BRB, Ruiyi Acquisition Corporation, and Nemus Sub. All intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements used in determining stock based compensation expense, estimated legal contingencies and estimates related to the Company's estimation of the percentage of completion under its research and development contracts, which are not readily apparent from other sources. Risks and Uncertainties The Company’s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential market for the Company’s product candidates, uncertainties related to the current global environment, including economic factors such as inflation, and risks related to the global supply chain disruptions (Note 1), risks related to operating in a virtual environment, results of research and development activities, uncertainties surrounding regulatory developments in the United States, Canada, the European Union, and Australia and the Company’s ability to attract new funding. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The carrying values of those investments approximate their fair value due to their short maturity and liquidity. Cash and cash equivalents includes cash on hand and amounts on deposit with financial institutions, which amounts may at times exceed federally insured limits. The Company has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk. As of December 31, 2024 there is no restricted cash on the balance sheet (refer to Note 11). As of December 31, 2023, restricted cash on the balance sheet collateralized an irrevocable letter of credit. Property and Equipment, net Property and equipment is stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally three to five years . Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do not extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. F-9 Fair Value Measurements Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the “exit price”) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities. Level 2: Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. The carrying values of the Company’s financial instruments approximate their fair value due to their short maturities. Income Taxes The Company accounts for deferred income tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, net operating loss carryforwards (the “NOLs”) and other tax credit carryforwards. These items are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period that includes the enactment date. Any interest or penalties would be recorded in the Company’s Consolidated Statements of Operations in the period incurred. When necessary, the Company recognizes interest and penalties related to income tax matters in income tax expense. The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion or all of the deferred tax assets will not be realized. In making such determinations, management considers all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. Due to the substantial doubt related to the Company’s ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2024 and 2023. As a result of this valuation allowance, there are no income tax benefits reflected in the accompanying Consolidated Statements of Operations to offset pre-tax losses. The Company recognizes a tax benefit from uncertain tax positions when it is more likely than not (50%) that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits of the position. Convertible Instruments The Company adopted ASU 2020-06. Since the adoption of ASU 2020-06, the Company recorded its convertible debt at face value less unamortized issuance costs. Issuance costs are amortized to Interest expense in its Consolidated Statements of Operations using the effective interest method over the expected term of the convertible debt. The Company assesses the short-term and long-term classification of its convertible debt on each balance sheet date. Whenever the holders have a contractual right to convert, the carrying amount of the convertible debt is reclassified to current liabilities. Warrants Issued in Connection with Financings The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense, net in the Consolidated Statements of Operations. Debt Issuance Costs and Interest Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. F-10 Research and Development Expenses and Licensed Technology Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third party contract research organizations and investigative sites; third party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company’s preclinical; and clinical drug development activities, other expenses and equipment and laboratory supplies. Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. None of the costs associated with the use of licensed technologies has been capitalized to date. Similarly, costs incurred to acquire in-process research and development ("IPR&D") are charged to research and development expense in the situation where the Company has not identified an alternative future use and are capitalized in the situation where there is an alternative future use. All costs associated with the acquisition of IPR&D have been expensed to date. Stock-Based Compensation Expense Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the fair value is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. Upon the exercise of stock option awards, the Company's policy is to issue new shares of its common stock. The Company uses the Black-Scholes valuation method for estimating the grant date fair value of stock options using the following assumptions: • Volatility - Stock price volatility is estimated over the expected term based on a blended daily rate of industry peers stock volatility. • Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award. • Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted. • Dividends - The dividend yield assumption is based on the Company’s history and expectation of paying no dividends in the foreseeable future. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. Loss Per Common Share The Company applies ASC No. 260, Earnings per Share in calculating its basic and diluted loss per common share. Basic loss per common share is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. Diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, restricted stock units, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is anti-dilutive. For additional information regarding the loss per share (see Note 9). Leases The Company applies ASU, No. 2016-02, Leases (Topic 842), in accounting for operating lease arrangements. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in the lease contract is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liability, current portion and operating lease liability, net of current portion. F-11 Asset Acquisitions The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen is met, the transaction is accounted for as an asset acquisition. If the screen is not met, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets. For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Common stock, warrants and options issued as consideration in an asset acquisition are generally measured based on the acquisition date fair value of the equity interests issued. The Company refers to ASC 718 and utilizes a Black-Scholes Model to value the options and warrants issued is an asset acquisition and includes the fair value of such awards in the purchase consideration. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. Consideration deposited into escrow accounts are evaluated to determine whether it should be included as part of the cost of an asset acquisition or accounted for as contingent consideration. Amounts held in escrow where we have legal title to such balances but where such accounts are not held in the Company's name, are recorded on a gross basis as an asset with a corresponding liability in our consolidated balance sheet. Unless an acquired asset is expensed at the date of acquisition, in accordance with other applicable GAAP, the cost of an asset acquisition, including transaction costs, are allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. However, as of the date of acquisition, if certain assets are carried at fair value under other applicable GAAP the consideration is first allocated to those assets with the remainder allocated to the non-monetary identifiable assets based on a relative fair value basis. Government Assistance The Company adopted ASU 2021-10 Government Assistance on January 1, 2022. The Company accounts for the tax rebates received from the Australian Taxation Office ("ATO") under such guidance. The Company accounts for the rebates that it receives under the AusIndustry research and development tax incentive program under the income recognition model of IAS 20. Under this model, when there is reasonable assurance that the rebate will be received, the Company recognizes the income from the tax rebate as an offset to research and development expense during the period which the benefit applies to the research and development costs incurred. The total tax rebates received under the AusIndustry incentive program were $ 493,362 for the year ended December 31, 2024 related to incentives earned in the prior year and $ 180,374 for the year ended December 31, 2023. As of December 31, 2024 and 2023, the Company has recognized $ 8,151 and $ 540,604 , respectively, in other current assets in its Consolidated Balance Sheets. Foreign Currency Translation The Company’s reporting currency and the functional currency of its foreign subsidiaries is the United States dollar. The local currencies of its foreign subsidiaries are the Canadian Dollar (“CAD”) or Australian dollar (“AUD”). Assets and liabilities are remeasured based on the exchange rates at the balance sheet date 0.6952 for the CAD, 0.623 for the AUD as of December 31, 2024 and 0.7549 for the CAD and 0.6818 for the AUD as of December 31, 2023, while expense accounts are remeasured at the weighted average exchange rate for the period 0.7023 for the CAD and 0.6342 for the AUD for the year ended December 31, 2024 and 0.7453 for the CAD and 0.6697 for the AUD as of December 31, 2023. Equity accounts are remeasured at historical exchange rates. The resulting remeasurement adjustments are recognized in general and administrative expenses in the consolidated financial statements. During the years ended December 31, 2024 and 2023, the Company recorded foreign currency remeasurements of $ 148,023 and $ 61,767 , respectively, which are reflected in general and administrative expenses in the accompanying Consolidated Statements of Operations. Foreign currency gains and losses resulting from transactions denominated in foreign currencies are recorded in the Consolidated Statements of Operations. During the years ended December 31, 2024 and 2023, the Company recorded foreign currency transaction loss of $ 49,986 and gain of $ 9,143 , respectively, which is reflected in the general and administrative expenses in the accompanying consolidated statement of operations. F-12 Commitments and Contingencies The Company follows ASC 440, Commitments and ASC 450, Contingencies , subtopic 450-20 to report accounting for contingencies and commitments respectively. Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or un-asserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or un-asserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein. If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Refer to Note 11 for additional information. In accordance with ASC 450, Contingencies, subtopic 450-20, the Company does not reflect a contingency that may result in a gain until it is realized. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Account Standards Update (“ASU”) No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. The amendments in this ASU are effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company adopted ASU 2016-13 as of January 1, 2023 and the adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The new standard reduces the number of accounting models for convertible debt instruments, amends the accounting for certain contracts in an entity's own equity, and modifies how certain convertible instruments and contracts that may be settled in cash or shares impact the calculation of diluted earnings per share. Specifically, the guidance removes certain accounting models that separate the embedded conversion features from the host contract for convertible instruments and requires the use of the if-converted method to calculate diluted earnings per share. The adoption of this standard did not have an impact on the Company's consolidated financial statements. In November 2023, the FASB issued ASU 2023-07, S egment Reporting (Topic 280) : Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company adopted the ASU and determined that its adoption did not have a material impact on the Company’s consolidated financial statements and related disclosures. As defined in the ASU, operating segments are components of an enterprise about which discrete financial information is regularly provided to the CODM in making decisions on how to allocate resources and assess performance for the organization. The Company operates and manages its business as one reportable and operating segment — pharmaceutical development. The Company’s CODM is the Chief Executive Officer. The Company’s CODM reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. See Segment Note 12. F-13 Recent Accounting Pronouncements Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures . This ASU requires greater disaggregation of information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. This ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. This ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. This ASU should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures. In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses , which requires additional disclosure of the nature of expenses included in the income statement. The standard requires disclosures about specific types of expenses included in the expense captions presented in the income statement as well as disclosures about selling expenses. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements should be applied on a prospective basis while retrospective application is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures. 3. Asset Acquisitions and Dispositions BRB Acquisition On August 18, 2023, the Company acquired BRB pursuant to the BRB Merger Agreement. The purpose of the acquisition was to acquire BRB's clinical asset, nimacimab, an antibody targeting the CB1 receptor. Pursuant to the BRB Acquisition, the Company issued 3,872,184 shares of common stock to the former preferred shareholders of BRB equal to $ 20,000,000 in base merger consideration priced at $ 5.16 . In addition, the former preferred shareholders of BRB were entitled to additional merger consideration for each dollar invested in the August 2023 PIPE Financing (as defined in Note 7). Because the August 2023 PIPE Financing and the BRB Acquisition occurred contemporaneously and in contemplation of each other, in accounting for the transaction, the Company allocated the shares issued as additional merger consideration between the BRB Acquisition and PIPE Financing using a residual allocation method, whereby the fair value of the consideration transferred was first allocated to the monetary assets and August 2023 PIPE Financing proceeds with the remainder allocated to the IPR&D asset. As a result, 1,564,194 additional shares of common stock were allocated to the BRB Acquisition. Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition: August 18, 2023 Purchase consideration Common stock $ 21,609,586 (a) Total consideration $ 21,609,586 Assets acquired and liabilities assumed: IPR&D asset $ 21,215,214 Cash and cash equivalents 1,076,740 Prepaid expenses 4,800 Accounts payable ( 73,473 ) Other current liabilities ( 613,695 ) Total net assets acquired $ 21,609,586 (a) Equal to the aggregate common shares issued of 5,436,378 , multiplied by the Company's closing stock price of $ 3.975 as of August 18, 2023. F-14 The cost to acquire the IPR&D asset related to nimacimab was expensed on the date of the BRB Acquisition as it was determined to have no future alternative use. Accordingly, costs associated with the BRB Acquisition to acquire the asset were expensed as incurred. Acquisition of Emerald Health Therapeutics, Inc. As of December 31, 2024 the Company has divested both of EHT's former operating entities, and the divestiture of substantially all of EHT's assets, including the real estate held by AVI, is complete. Sale of real estate The wind down of EHT's operations included the disposition of real estate held by AVI (the "AVI building"). At the time of the Company’s acquisition of EHT on November 10, 2022 (the “EHT Acquisition”) , none of the purchase consideration was allocated to the fair value of the AVI building. As a result of the sale of the AVI building, for the year ended December 31, 2024, the Company recorded a gain of $ 1,145,141 as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Consolidated Statements of Operations. Divestiture of VDL, Release and Discharge Agreement On November 10, 2022, EHT and C3 Centre Holding Inc., a third-party, entered into a share purchase agreement, executed as of November 8, 2022, as amended (the " Verdélite SPA") pursuant to which C3 would acquire all of the outstanding shares of VDL, the holder of EHT's most significant real estate asset. On February 9, 2023, u pon closing the transactions contemplated by the Verdélite SPA, the Company sold all of the outstanding shares of VDL for an aggregate purchase price of approximately $ 9,451,233 . Prior to closing the EHT Acquisition, EHT received a $ 557,705 cash deposit, which was considered in the sale as of the closing date. Upon closing, the Company received gross proceeds, net of legal and advisory fees as of the closing date, of $ 5,532,266 , with the remainder of the purchase price to be paid in accordance with an installment schedule as determined by the Verdélite SPA. The Company recognized the sale of VDL when control transferred on February 9, 2023. In accordance with recognition guidance, the Company has determined to fully reserve for the remaining receivables and will record a gain on the sale when additional cash payments are received. For the year ended December 31, 2023, the Company has recorded a loss on sale of asset of $ 307,086 in other expense based on the difference between the carrying amount of the assets sold and the net cash proceeds. On July 17, 2024, the Company entered into a transaction, release and discharge agreement with the purchaser of VDL. Under the transaction, release and discharge agreement, the purchase price of VDL was adjusted in exchange for a full release of any future claims by VDL against the Company. As part of the agreement, the parties agreed to a reduced installment payment schedule for the remaining aggregate balance of the purchase price of $ 2,047,080 through December 2027. The remainder of the purchase price receivable bears interest at 8 %. Upon signing the transaction, release and discharge agreement, the Company received the first ins tallment payment of $ 213,404 recorded as a (Gain) Loss from Asset Sales within the Other Income and Expense section of the Company's Consolidated Statement of Operations. 4. Property and Equipment, Prepaid Expenses, Other Current Assets and Liabilities Property and equipment, net consists of the following: As of December 31 2024 2023 Machinery and equipment $ 1,527,419 $ 78,024 Furniture and fixtures 18,184 — Computer equipment 96,744 46,732 Leasehold improvements 23,918 13,954 Total property and equipment, gross 1,666,265 138,710 Less: accumulated depreciation and amortization ( 233,513 ) ( 95,434 ) Total property and equipment, net $ 1,432,752 $ 43,276 Depreciation and amortization expense for the twelve months ended December 31, 2024 and twelve months ended December 31, 2023 was $ 203,757 and $ 49,909 , respectively. F-15 Prepaid expenses consist of the following: As of December 31 2024 2023 Prepaid clinical expenses $ 13,078 $ 61,352 Total other prepaid expenses 188,884 132,907 $ 201,962 $ 194,259 Other current assets consist of the following: As of December 31 2024 2023 AusIndustry incentive $ 8,151 $ 540,604 Vendor deposits 1,997,274 403,439 Other tax receivables 5,065 158,242 Other current assets 199,054 17,644 $ 2,209,544 $ 1,119,929 Other current liabilities consist of the following: As of December 31 2024 2023 Research and development costs $ 325,415 $ 467,784 Legal expenses 114,359 251,466 EHT Acquisition related liability — 180,897 Consulting and professional fees 109,375 69,468 Other accrued liabilities 105,052 22,190 $ 654,201 $ 991,805 5. Warrants There are significant judgements and estimates inherent in the determination of the fair value of the Company’s warrants. These judgements and estimates include assumptions regarding the Company’s future operating performance and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2). F-16 Warrants Warrants vested and outstanding as of December 31, 2024 are summarized as follows: Source Exercise Price Remaining Term (Years) Number of Warrants Outstanding 2015 Common Stock Warrants 1,250.00 0.31 400 2016 Common Stock Warrants to Service Providers 287.50 1.83 160 2020 Common Stock Warrants to Placement Agent 20.00 0.58 32,668 2021 Inducement Warrants 37.50 1.57 84,667 2021 Inducement Warrants to Placement Agent 47.00 1.57 5,927 2021 Common Stock Warrants 22.50 1.74 311,113 2021 Common Stock Warrants to Placement Agent 27.50 1.74 21,778 February 2020 EHT Common Stock Warrants* 37.25 0.11 80,694 August 2023 Convertible Note Common Stock Warrants 5.16 8.63 340,000 August 2023 PIPE Financing Common Stock Warrants 5.16 8.63 2,325,537 January 2024 Pre-Funded Warrants Common Stock 0.001 Indefinite 8,677,166 Total warrants outstanding as of December 31, 2024 11,880,110 As of December 31, 2024, all of the Company's warrants are fully vested. January 2024 Pre-Funded Warrants In connection with the January 2024 PIPE Financing (as defined in Note 7), the Company issued the Pre-Funded Warrants (as defined in Note 7). The Pre-Funded Warrants have an exercise price of $ 0.001 per share, and were exercisable immediately upon issuance until exercised in full. The gross proceeds from the issuance of these Pre-Funded Warrants was $ 22,991,015 . The Company determined that the Pre-Funded Warrants are freestanding instruments that do not meet the definition of a liability or derivative. The Pre-Funded Warrants are indexed to the Company’s common stock and meet all other conditions for equity classification. Accordingly, the Pre-Funded Warrants are classified as equity and are accounted for as a component of additional paid-in capital at the time issued. The Company also determined that the Pre-Funded Warrants should be included in the determination of basic and diluted earnings per share. August 2023 PIPE Financing Common Stock Warrants In connection with the August 2023 PIPE Financing (as defined in Note 7), the Company issued 2,325,537 common stock warrants. The warrants were equity classified at issuance and $ 4,784,894 of the gross proceeds from the August 2023 PIPE Financing were allocated to the common stock warrants on a relative fair value basis. The warrants vested immediately upon issuance and the fair value of $ 7,881,972 was determined using the Black-Scholes Merton option pricing model with the following assumptions: August 18, 2023 Dividend yield 0.00 % Volatility factor 87.88 % Risk-free interest rate 4.26 % Expected term (years) 10.00 Underlying common stock price $ 5.16 F-17 August 2023 Convertible Note Common Stock Warrants In connection with the Convertible Note (as defined in Note 6), the Company issued 340,000 common stock warrants. The warrants were equity classified at issuance and $ 931,576 of the gross proceeds from the Convertible Note were allocated to the common stock warrants on a relative fair value basis. The warrants vested immediately upon issuance and the fair value of $ 1,144,886 was determined using the Black-Scholes Merton option pricing model with the following assumptions: August 18, 2023 Dividend yield 0.00 % Volatility factor 87.88 % Risk-free interest rate 4.26 % Expected term (years) 10 Underlying common stock price $ 5.16 February 2023 Sciences Warrant Exercises Effective February 16, 2023, the Company and Sciences entered into a Master Transaction Agreement (the "MTA"). Under the MTA, Sciences agreed to exercise 66,566 common stock warrants at $ 4.25 per share (the "MTA Warrants"). Under the MTA, the parties agreed that the aggregate proceeds from the exercise of the MTA Warrants of $ 282,906 was to be paid through a reduction of the outstanding borrowings under the Amended Credit Agreement (as defined in Note 6). On February 22, 2023, the Company issued 66,566 shares of common stock to Sciences in connection with the exercise of the MTA Warrants (as defined in Note 7). 6. Debt The Company’s convertible debt consists of the following: As of December 31, 2023 Total principal value of convertible note - related party, net of debt discount $ 5,000,000 Unamortized debt discount ( 610,749 ) Unamortized debt issuance costs ( 17,253 ) Carrying value of total convertible debt—related party $ 4,371,998 Convertible Note - Related Party On August 15, 2023, the Company entered into a Secured Note and Warrant Purchase Agreement with MFDI, LLC (“MFDI”), pursuant to which the Company issued to MFDI a $ 5,000,000 secured convertible promissory note (the "Convertible Note") and a warrant to purchase 340,000 shares of common stock on August 18, 2023 (the "Convertible Note Financing") (Note 5). The Convertible Note accrued interest at a rate of 10 % per annum and had a fixed conversion price at $ 5.16 . On August 8, 2024, MFDI exercised the conversion option under the Convertible Note and converted the full principal balance. This conversion resulted in the issuance of 968,973 shares of the Company's common stock and the payment of accrued interest in cash. In the original accounting for the Convertible Note, the Company allocated $ 4,068,424 in proceeds to the debt host and $ 931,576 in proceeds to the freestanding warrants based on relative fair value. The debt discounts of $ 931,576 and $ 26,316 related to the warrants, and debt issuance costs, respectively, were amortized over the term of the Convertible Note using the effective interest rate method. Amortization of the debt discount was recognized as non-cash interest expense in Other expense within the Consolidated Statements of Operations. In addition, the Company recorded $ 6,026 in equity issuance costs as a deduction to additional paid in capital in the Statements of Stockholders' Deficit. Accrued interest on the Convertible Note was payable quarterly within 30 days of the last day of each calendar quarter. The debt discounts related to the warrants, and debt issuance costs, were amortized over the term of the Convertible Note using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense in Other (income) expense within the Consolidated Statements of Operations. Through the date of conversion, the Convertible Note is classified as Level 2 of the fair value hierarchy model based on market prices that can be corroborated with observable market data for the Company's common stock. F-18 For the year ended December 31, 2024, the effective interest rate on the Convertible Note was 31.39 %. Bridge Loan On July 24, 2023, the Company entered into a loan agreement in the principal amount of $ 250,000 (the “Bridge Loan”) with MFDI, LLC. The Bridge Loan was obtained in order to provide bridge financing for the operations of the Company until it completed the BRB Acquisition. Concurrent with the closing of the BRB Acquisition, August 2023 PIPE Financing and Convertible Note Financing, the Bridge Loan was cancelled and converted into an investment in the August 2023 PIPE Financing (as defined in Note 7). All interest and rights related to the Bridge Loan were concurrently cancelled. Insurance Premium Loan Payable On February 28, 2023, the Company entered into an annual financing arrangement for a portion of its Directors and Officers Insurance Policy (the “D&O Insurance”) with First Insurance Funding in an amount of $ 203,884 . The loan was payable in equal monthly installments of $ 23,374 , matured on January 31, 2024, and bore interest at a rate 4.24 % per annum. As of December 31, 2023 a total of $ 21,238 remained in prepaid expenses and the loan has been repaid. On February 28, 2022, the Company entered into an annual financing arrangement for a portion of its Directors and Officers Insurance Policy with First Insurance Funding in an amount of $ 275,537 . The loan was payable in equal monthly installments of $ 31,150 , matured on January 31, 2023 and bore interest at a rate 4.17 % per annum. Interest Expense The Company’s interest expense consists of the following: Year Ended December 31, 2024 2023 Related party interest expense – stated rate $ 302,740 $ 202,254 Insurance premium loan payable – stated rate — 6,485 Legal judgment estimated interest (income) expense ( 234,750 ) 234,750 Bond premium 59,929 59,929 Premium on irrevocable letter of credit 22,383 69,861 Other interest expense — 3,100 Non-cash interest expense: Amortization of debt discount 582,550 320,828 Amortization of transaction costs 16,456 9,063 $ 749,308 $ 906,270 7. Stockholders’ Equity and Capitalization The Company reserved shares of common stock, on an as-if converted basis, for issuance as follows: Year Ended December 31, 2024 2023 Options issued and outstanding 3,036,603 498,298 Awards available for grant under the Amended and Restated Omnibus Incentive Plan 119,046 487,672 Shares available for issuance under ESPP Plan 192,016 112,000 Shares for issuance under our Inducement Plan 286,500 — Restricted stock units issued and outstanding 503,113 847,777 Unreleased restricted stock awards issued to a service provider — 5,000 Common stock underlying the Convertible Note - Related Party — 968,973 Warrants issued and outstanding 11,880,110 3,280,940 16,017,388 6,200,660 F-19 Increase to Authorized Shares of Capital Stock On November 6, 2023, the Company increased its authorized shares of common stock to 100,000,000 . PIPE Financings January 2024 PIPE Financing On January 29, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on January 31, 2024, the Company issued an aggregate of 11,713,664 shares of common stock and 9,978,739 pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 9,978,739 shares of common stock (the "January 2024 PIPE Financing") for an aggregate purchase price of $ 49,991,010 . The January 2024 PIPE Financing was priced at $ 2.31 per common share and $ 2.30 per Pre-Funded Warrant based on the 5-day average share price preceding January 29, 2024. The Pre-Funded Warrants are exercisable at any time for an exercise price of $ 0.001 . In connection with the January 2024 PIPE Financing, the Company incurred $ 3,823,752 in direct equity issuance costs for net proceeds of $ 46,167,258 . March 2024 PIPE Financing On March 11, 2024, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which on March 13, 2024, the Company issued an aggregate of 4,000,000 shares of common stock (the "March 2024 PIPE Financing") for an aggregate purchase price of $ 40,000,000 . The March 2024 PIPE Financing was priced at $ 10.00 per common share. In connection with the March 2024 PIPE Financing, the Company incurred $ 2,610,695 in direct equity issuance costs for net proceeds of approximately $ 37,389,305 . August 2023 PIPE Financing Concurrently with the BRB Acquisition and the Convertible Note Financing, on August 15, 2023, the Company entered into the August 2023 PIPE Financing, pursuant to which on August 18, 2023, the Company issued an aggregate of 2,989,981 shares of common stock and accompanying warrants to purchase up to 2,325,537 shares of common stock (the "August 2023 PIPE Financing Common Stock Warrants ") (Note 5 ) for an aggregate purchase price of $ 12,000,000 . The August 2023 PIPE Financing was priced at $ 5.16 per share based on the 60-day volume-weighted average share price preceding August 15, 2023. The two lead investors in the August 2023 PIPE Financing were also former preferred shareholders of BRB. As an incentive to participate in the August 2023 PIPE Financing, the BRB Merger Agreement entitled each BRB stockholder participating in the August 2023 PIPE Financing an additional share of common stock for every share of common stock purchased in the August 2023 PIPE Financing. As a result, the two former BRB preferred shareholders who participated in the August 2023 PIPE Financing were issued an additional 2,228,638 shares of common stock. Because the August 2023 PIPE Financing and BRB Acquisition occurred contemporaneously and in contemplation of one another, the Company allocated 664,444 of the common shares issued in the BRB Acquisition to the August 2023 PIPE Financing (Note 3). In connection with the August 2023 PIPE Financing, the Company incurred $ 265,053 in direct equity issuance costs for net proceeds of $ 11,734,947 . Conversion of Debt On August 8, 2024, the Company issued 968,973 shares of common stock to MFDI upon conversion in full of the Convertible Note (see Note 6). During the year ended December 31, 2023, the Company issued 165,517 shares of common stock to Sciences. The shares were issued in conjunction with the MTA, in exchange for the remaining principal balance plus accrued interest less the aggregate exercise price of $ 282,905 from the exercise of the MTA Warrants in the amount of $ 1,597,236 at a conversion price of $ 9.65 (Note 6). BRB Acquisition On August 18, 2023, the Company issued an aggregate of 5,436,378 shares of common stock in connection with the BRB Acquisition (Note 3). F-20 Stock Issued for Services For the twelve months ended December 31, 2024 and 2023, the Company released 5,000 and 5,000 shares, respectively, of common stock to a service provider (Note 8). Warrant Exercises Prefunded Warrant Exercise On July 1, 2024, 1,301,573 pre-funded warrants issued in the January 2024 PIPE Financing with an intrinsic value of $ 10,424,294 were exercised on a cashless basis, resulting in the issuance of 1,301,573 shares of Company's common stock. Common Stock Warrant Exercises During the year ended December 31, 2023, 66,566 of the outstanding stock warrants held by Sciences in conjunction with the MTA, with an intrinsic value of $ 332,830 were exercised in exchange for 66,566 shares of common stock for proceeds of $ 282,906 which were applied to the balance of the Amended Credit Agreement (Note 6). Restricted Stock Units Released During 2024 a total of 634,664 RSUs were vested and settled. On December 14, 2023, the Company settled 5,333 RSUs that had vested to executives of the Company (Note 8). 8. Stock-Based Compensation Stock Incentive Plan On October 31, 2014, the Board approved the Company’s 2014 Omnibus Incentive Plan (the “2014 Plan”). The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. On June 14, 2022, the Board approved the 2014 Amended and Restated Omnibus Incentive Plan (the “2014 Amended and Restated Plan”) which replaced the 2014 Plan in its entirety. On September 29, 2023, the Board and Majority Stockholders adopted and approved Amendment No. 1 to the 2014 Amended and Restated Plan. Amendment No. 1 to the 2014 Amended and Restated Plan became effective on November 6, 2023. On October 22, 2024, the second amendment and restatement of the Company's 2014 Amended and Restated Plan was approved to increase the number of shares of the Company's common stock issuable thereunder by 1,535,655 to increase the number of incentive stock options that may be granted thereunder to 4,000,000 , extend the expiration date of the plan to September 10, 2034, update the name of the plan to the “Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan” and make certain administrative amendments (as so amended and restated, the "Amended and Restated Plan"). The Amended and Restated Plan, among other things, , provides that each January 1 beginning in 2023 and ending on (and including) January 1, 2032 the number of shares will increase by 5 % of the outstanding shares of Common Stock as of the prior December 31, unless the Board of Directors of the Company decides to a lesser increase. As of December 31, 2024, the shares available for future grant under the Amended and Restated Plan are as follows: Shares Available for Grant Available as of December 31, 2023 482,339 Share pool increase 2,153,117 Forfeited 169,690 RSU grants ( 275,000 ) Option grants ( 2,411,100 ) Available as of December 31, 2024 119,046 F-21 2024 Inducement Equity Incentive Plan On July 2, 2024, the Board adopted the Skye Bioscience, Inc. 2024 Inducement Equity Incentive Plan (as amended and restated, the "Inducement Plan"). The Inducement Plan was adopted in order to grant share-based awards to newly hired employees as an inducement to join the Company. The terms of the Inducement Plan are substantially similar to the terms of the Company’s 2014 Amended and Restated Plan with the exception that awards may only be made to an employee who has not previously been an employee or member of the Board of Directors of the Company if the award is in connection with commencement of employment. The Company has reserved 600,000 shares of the Company’s common stock for issuance pursuant to awards granted under the Inducement Plan. As of December 31, 2024, the shares available for future grant under the Amended and Restated Plan are as follows: Shares Available for Grant Available as of December 31, 2023 — Share pool increase 600,000 Forfeited 40,000 RSU grants ( 15,000 ) Option grants ( 338,500 ) Available as of December 31, 2024 286,500 Stock Options Options granted under the Company's equity incentive plans expire no later than ten years from the date of grant. Options granted under the the Company's equity incentive plans may be either incentive or non-qualified stock options. For incentive and non-qualified stock option grants, the option price shall be at least 100 % of the fair value on the date of grants, as determined by the Company’s Board of Directors. If at any time the Company grants an option, and the optionee directly or by attribution owns stock possessing more than 10 % of the total combined voting power of all classes of stock of the Company, the option price shall be at least 110 % of the fair value and shall not be exercisable more than five years after the date of grant. The shares issued generally vest over a period of one to four years from the date of grant. The following is a summary of option activities under the Company’s Amended and Restated Plan and the Inducement Plan for the year ended December 31, 2024: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value* Outstanding, December 31, 2023 498,298 $ 8.96 7.24 $ 20,441 Granted 2,749,600 7.97 Exercised ( 1,605 ) 3.50 Forfeited ( 16,848 ) 78.91 Cancelled ( 192,842 ) 8.22 Outstanding, December 31, 2024 3,036,603 $ 7.72 8.91 $ 22,624 Exercisable, December 31, 2024 707,396 $ 10.55 6.63 $ 7,069 Vested and expected to vest, December 31, 2024 3,036,603 $ 7.72 8.91 $ 22,624 *The aggregate intrinsic value is the sum of the amounts by which the quoted market price of the Company’s stock exceeded the exercise price of the stock options at December 31, 2024 for those stock options for which the quoted market price was in excess of the exercise price ("in-the-money options"). The weighted-average grant-date fair value of stock options granted for the years ended December 31, 2024 and 2023, was $ 6.04 and $ 2.95 , respectively. The total fair value of the stock options that vested during the years ended December 31, 2024 and 2023 was $ 4,034,671 and $ 512,470 , respectively. F-22 The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model under the following assumptions: Year Ended December 31, 2024 2023 Dividend yield 0.00 % 0.00 % Risk-free interest rate 3.69 - 4.48 % 3.86 - 4.61 % Expected term (years) 5.27 - 6.08 5.27 - 6.08 Volatility 81.73 - 99.96 % 87.93 - 127 % Restricted Stock Units On February 29, 2024, the Company granted restricted stock units ("RSUs") to its executive management team and to certain members of the Board with market-based vesting conditions. The RSUs are eligible to vest subject to the achievement and attainment of certain market capitalization target goals and share price targets (market-based vesting conditions). The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market and performance conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. The fair value of the Company's market-based RSUs were estimated on the date of grant under the following assumptions: Year Ended December 31, 2024 2023 Dividend yield 0.00 % 0.00 % Volatility factor 93.71 % 87.4 - 87.9 % Risk-free interest rate 4.16 % 4.21 - 4.54 % Derived service periods (years) 1.27 - 2.48 0.81 - 3.11 On August 22, 2024, the Board approved a modification to the terms of the RSUs issued on August 25, 2023, and September 29, 2023 to its executive management team and to a member of the Board. The vesting condition was modified from a performance-based condition to a market-based condition. Since the performance condition under the original award was improbable of being met at the time of the modification, no expense was previously recognized. Therefore, on the modification date, the Company established a new fair value and will recognize the expense over the derived service period. The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of the awards. The fair value of the Company's market-based RSUs were estimated on the modification date under the following assumptions: August 22, 2024 Dividend yield 0.00 % Volatility factor 94.3 % Risk-free interest rate 3.76 % Derived service periods (years) 2.11 On August 25, 2023, the Company granted RSUs to its executive management team and to certain members of the Board with market and performance based conditions. The RSUs are eligible to vest subject to the achievement and attainment of certain market capitalization target goals (market-based conditions) or the achievement of a successful exit (a performance-based condition); provided, however, that no RSUs shall vest until the Compensation Committee of the Board determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. F-23 The fair value of the Company's performance-based RSUs were estimated on the date of grant under the following assumptions: Year Ended December 31, 2023 Dividend yield 0.00 % Volatility factor 87.4 - 87.9 % Risk-free interest rate 4.21 - 4.54 % Derived service periods (years) 0.81 - 3.11 The following is a summary of restricted stock unit activity during the year ended December 31, 2024: Number of Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2023 847,777 $ 3.66 Granted 290,000 13.87 Released ( 634,664 ) 3.58 Unvested, December 31, 2024 503,113 $ 9.62 The Company used the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market and performance conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term. Awards Granted Outside the 2014 Amended and Restated Plan During the year ended December 31, 2023, the Company granted shares of common stock to a non-employee consultant for investor relations services. Half of the shares were issued upon entering each service contract and the remaining half was issued on September 30, 2024. The following is a summary of restricted stock activity outside of the 2014 Amended and Restated Plan during the year ended December 31, 2024: Number of Shares Weighted Average Grant Date Fair Value Unvested, December 31, 2023 5,000 $ 1.55 Granted — — Released ( 5,000 ) — *Unvested, December 31, 2024 — $ — Stock-Based Compensation Expense Stock Compensation Adjustments Related to Board Member Resignations On July 2, 2024, the Board accepted the resignations of several Board members effective August 1, 2024. Concurrently, the Board approved a modification to the option awards granted such Board members, which modification accelerated the vesting of all unvested options as of the resignation date and extended the post-termination exercise period to December 31, 2025. As a result of the modification, the Company recognized $ 274,019 in incremental stock compensation expense during the year ended December 31, 2024. F-24 The Company recognizes stock-based compensation expense using the straight-line method over the requisite service period. The Company recognized stock-based compensation expense, including compensation expense for warrants with vesting provisions issued to a service provider (Note 5), and the RSUs discussed above, in its Consolidated Statements of Operations as follows: Year Ended December 31, 2024 2023 Research and development $ 1,514,921 $ 188,886 General and administrative 6,802,559 798,624 $ 8,317,480 $ 987,510 The total amount of unrecognized compensation cost was $ 14,725,872 as of December 31, 2024. This amount will be recognized over a weighted-average period of 2.73 years. 2022 Employee Stock Purchase Plan In June 2022, the Board approved the 2022 Employee Stock Purchase Plan (the "ESPP"), under which the Company may offer eligible employees the option to purchase common stock at a 15 % discount to the lower of the market value of the stock at the beginning or end of each participation period under the terms of the ESPP. Total individual purchases in any year are limited to 15 % of compensation. The ESPP was approved by the Company's stockholders on September 30, 2022. As of December 31, 2024, no shares were issued under the ESPP. The compensation expense, computed using the Black-Scholes model was immaterial. 9. Loss Per Share of Common Stock The following tables are a reconciliation of the numerators and denominators used in the calculation of basic and diluted net loss per share computations: For the Year Ended December 31, 2024 Loss (Numerator) Shares (Denominator) Per-Share Amount Net loss $ ( 26,567,123 ) Basic EPS and diluted EPS Net loss available to common stockholders ( 26,567,123 ) 36,486,519 $ ( 0.73 ) For the Year Ended December 31, 2023 Income (Numerator) Shares (Denominator) Per-Share Amount Net loss $ ( 37,644,784 ) Basic EPS and diluted EPS Net loss available to common stockholders ( 37,644,784 ) 7,006,038 $ ( 5.37 ) F-25 The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive: Year Ended December 31, 2024 2023 Stock options 3,036,603 498,298 Unvested restricted stock units 503,113 847,777 Unvested restricted stock (service provider) — 5,000 Common shares underlying convertible debt — 968,973 Warrants 3,202,944 3,280,940 Total 6,742,660 5,600,988 10. Income Taxes The components of loss before the income tax provision consist of the following: Year Ended December 31, 2024 2023 United States $ ( 27,495,672 ) $ ( 25,799,330 ) Foreign 938,620 ( 11,841,854 ) Pre-tax loss and comprehensive loss from operations $ ( 26,557,052 ) $ ( 37,641,184 ) The components of the income tax expense consisted of the following: Year Ended December 31, Current income tax expense 2023 2022 Federal $ — $ — State 10,071 3,600 Foreign — — Total current income tax expense $ 10,071 $ 3,600 The Company is subject to taxation in the United States, various states, Australia, and Canada. The Company’s tax years for 2021 (federal), 2020 (States), 2020 (Australia) and 2020 (Canada) and forward are subject to examination by the United States, state, Australian, and Canadian tax authorities. However, to the extent allowed by law, the taxing authorities may have the right to examine periods where NOLs and credits were generated and carried forward and make adjustments up to the amount of the NOL and credit carryforwards. The Company is not currently under examination by any jurisdiction. At December 31, 2024, the Company had federal and state NOLs aggregating $ 123,364,920 and $ 140,454,552 , respectively. If not used, $ 46,622,953 of Federal NOLs and $ 140,454,552 of state NOLs will begin to expire in 2031, $ 76,741,967 of federal NOLs and $ — of state NOLs will carry forward indefinitely subject to an 80% limitation against taxable income. At December 31, 2024, the Company had Australia NOLs aggregating $ 312,009 which do not expire and $ 39,907,863 of Canadian NOLS which begin to expire in 2025. At December 31, 2024, the Company had Canadian capital loss carryforwards of approximately $ 56,552,498 which may be carried forward indefinitely. At December 31, 2024, the Company had federal and California research credit carryforwards of $ 4,764,557 and $ 2,187,816 , respectively. The federal research credit carry forwards will begin to expire in 2027, unless previously utilized. The California research credits will carry forward indefinitely. The Company’s NOLs and research credit carryforwards are subject to a reserve. Additionally, the Company had Canadian SR&ED credits as of December 31, 2024 of $ 865,827 which may be carried forward indefinitely. F-26 Utilization of the domestic NOL's and research credits could be subject to a substantial annual limitation due to ownership change limitations that may have occurred, or that could occur in the future, as required by Section 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOLs and credits that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change” as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. Upon the occurrence of an ownership change under Section 382 as outlined above, utilization of the NOLs and credits are subject to an annual limitation under Section 382 of the Code, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the NOLs and credits before utilization. While the Company has not performed a Section 382 study, multiple ownership changes may have already occurred as the Company raised capital through the issuance of stock. However, due to the existence of the valuation allowance for deferred tax assets, any potential change in ownership will not impact the Company’s effective tax rate. The tax effects of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows: As of December 31, Current deferred tax assets and (liabilities): 2024 2023 Net operating loss $ 41,627,022 $ 40,900,348 Capital loss carryforwards 14,986,412 17,157,029 Contingent legal accrual 381,938 1,320,526 Depreciation 477,024 663,197 Amortization 2,606 225,678 Research and development credits 4,112,293 3,694,501 Capitalized research and development costs 4,708,931 1,835,326 Lease liability 95,674 51,086 State taxes 1,092 777 Stock-based compensation 1,174,967 312,735 Other 270,088 350,331 Gross deferred tax assets 67,838,047 66,511,533 Valuation allowance ( 67,743,575 ) ( 66,461,557 ) Net deferred tax assets $ 94,472 $ 49,976 Deferred tax liabilities Right-of-use asset $ ( 94,472 ) $ ( 49,976 ) Total deferred tax liabilities ( 94,472 ) ( 49,976 ) Net deferred tax assets $ — $ — F-27 The provision for income taxes on earnings subject to income taxes differs from the statutory Federal rate at December 31, 2024 and 2023, due to the following: As of December 31, 2024 2023 Expected income tax benefit at federal statutory tax rate $ ( 5,576,981 ) $ ( 7,904,649 ) State income taxes, net of federal benefit ( 1,871,588 ) ( 847,810 ) Change in valuation allowance 2,522,618 3,167,507 Uncertain tax positions 2,562,991 1,008,482 Reduction in deferreds upon divestiture 839,873 — Stock compensation ( 46,422 ) 100,958 Research and development credits ( 1,374,591 ) ( 315,498 ) Rate adjustment 6,070 6,042 Foreign rate differential 2,396,433 ( 1,918,633 ) Divestiture of VDL — 2,269,297 In process research and development — 4,455,195 162(m) officers compensation 460,853 27,942 Other 90,815 ( 45,234 ) Provision for income taxes $ 10,071 $ 3,600 The Company records a valuation allowance against deferred tax assets to the extent that it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Due to the the substantial doubt related to the Company's ability to utilize its deferred tax assets, a valuation allowance for the full amount of the deferred tax assets has been established at December 31, 2024. During the year ended December 31, 2024, the valuation allowance increased by $ 1,282,018 . The Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company elects to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. Under the FASB’s accounting guidance related to income tax positions, among other things, the impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, the guidance provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. A reconciliation of the beginning and ending amounts of unrecognized tax positions are as follows: As of December 31, 2024 2023 Unrecognized tax positions, beginning of the year $ 6,432,143 $ 2,872,020 Gross increase - current period tax positions 3,073,575 1,243,191 Gross increase - prior period tax positions — 2,316,932 Gross decrease – prior period tax positions ( 7,277 ) — Unrecognized tax positions, end of year $ 9,498,441 $ 6,432,143 If recognized, none of the unrecognized tax positions would impact the Company’s income tax benefit or effective tax rate as long as the Company’s net deferred tax assets remain subject to a full valuation allowance. The Company does not expect any significant increases or decreases to the Company’s unrecognized tax positions within the next twelve months. The Company had no accrual for interest or penalties on the Company’s Consolidated Balance Sheets at December 31, 2024 and 2023 and has no t recognized interest and/or penalties in the Consolidated Statements of Operations for the years then ended . F-28 11. Commitments and Contingencies Office Leases The Company leases office space for its corporate headquarters, located at 11250 El Camino Real, Suite 100 San Diego, California 92130. The original lease term was effective from September 1, 2021 through October 31, 2023 and contained a renewal option for a two-year extension after the current expiration date. At the commencement date, the Company did not expect to exercise the renewal option, and has therefore excluded the option from the calculation of the right of use asset and lease liability. The lease provides for two months of rent abatement and the initial monthly rent is $ 8,067 per month with annual increases of 3 % commencing on November 1, 2022. The lease included non-lease components (i.e., property management costs) that are paid separately from rent, based on actual costs incurred, and therefore were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the lease term. The Company entered into an amended and restated lease agreement on June 27, 2023 for its corporate headquarters, extending the lease term to 36 months, retroactive to September 1, 2021 through October 31, 2026. The Company treated the amended and restated lease agreement as a single modified lease. On September 25, 2024, the Company entered into a new lease agreement for approximately 2,077 square feet of office space located at 632 Commercial Street, 5th Floor, San Francisco, California 94111. The lease has a term of three years and two months , beginning on October 01, 2024, with a monthly rent of $ 9,000 and annual increases of 3 %. This office space will support the Company's continued growth and operational needs as the Company expands its development activities. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the lease term. For the years ended December 31, 2024 and 2023, lease expense comprised of $ 130,658 and $ 97,986 , respectively in lease cost from the Company's non-cancellable operating leases. The remaining lease term and discount rate related to the operating lease are presented in the following table: December 31, 2024 Weighted-average remaining term – operating lease (in years) 2.62 Weighted-average discount rate – operating lease 11.41 % Future minimum lease payments as of December 31, 2024 are presented in the following table: Year: 2025 215,127 2026 202,876 2027 85,936 Total future minimum lease payments: 503,939 Less imputed interest 48,349 Total $ 455,590 Reported as: December 31, 2024 December 31, 2023 Operating lease liability $ 182,428 $ 72,038 Operating lease liability, net of current portion 273,162 171,230 Total lease liability $ 455,590 $ 243,268 General Litigation and Disputes From time to time, in the normal course of operations, the Company may be a party to litigation and other dispute matters and claims. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of complex legal proceedings are difficult to predict. An unfavorable outcome to any legal matter, if material, could have a materially adverse effect on the Company’s operations or financial position, liquidity or results of operations. F-29 Wendy Cunning vs Skye Bioscience, Inc. The Company is a party to a legal proceeding with a former employee alleging, among other things, wrongful termination, violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company's former management during the employee's employment term from March 2018 to July 2019. The case, entitled Wendy Cunning vs Skye Bioscience, Inc. , was filed in U.S. District Court (the "District Court") for the Central District of California (the “Cunning Lawsuit”). On January 18, 2023, a jury rendered a verdict in favor of Ms. Cunning and awarded her $ 512,500 in economic damages (e.g., lost earnings, future earnings and interest), $ 840,960 in non-economic damages (e.g., emotional distress) and $ 3,500,000 in punitive damages. On August 2, 2023, the District Court ruled on the plaintiff's motion for attorney fees and awarded the plaintiff $ 1,200,008 . Based on this order, the Company reduced the aggregate estimate for the legal contingency by $ 151,842 , the difference between the attorney fees awarded by the District Court and the Company's previous estimate. On August 17, 2023, the Company obtained a stay on enforcement of the judgment in the Cunning Lawsuit by posting an appeal bond in the amount of $ 9,080,202 . In March of 2023, the Company appealed the judgment in the Cunning Lawsuit to the United States Court of Appeals for the Ninth District (the "Ninth Circuit"). Subsequent to quarter end, on October 22, 2024, the Ninth Circuit issued its decision in the Company's favor which vacated the judgment and remanded the case back to the District Court for a new trial. As a result, the Company recovered the $ 9,080,202 restriction on its cash related to the bond during the year ended December 31, 2024. The District Court has set a scheduling conference for March 31, 2025. During the year ended December 31, 2024, management revised its assumptions related to its estimate of the legal contingency and the the Company reversed the accrued interest on the original judgment and recognized a gain of $ 4,234,717 in change in estimate for legal contingencies. In arriving at the conclusion that a significant portion of the estimated legal contingency should be reversed, the Company considered the following in revising its assumptions: • Advice from external advisors including its technical accounting advisors regarding the appropriate application of GAAP and legal counsel’s advice with regard to prior experience with similar cases, • the damages and potential attorney fee awards if the case were to be retried, including the likelihood of a subsequent loss if the Company were to be unsuccessful while giving consideration to the facts and circumstances that would be inadmissible due to the Ninth Circuit’s decision, • the likelihood of settlement and information obtained during settlement discussions prior to the first trial, • the Company’s possible defenses and counterclaims, and • the case history and the amount of the prior judgment. The final amount of the loss and loss recoveries remain uncertain. The ultimate amount of the potential loss may be significantly less than the amount of the revised legal contingency and there is no guarantee that the Company will be successful in its efforts to recover additional losses. The Company believes that it is at least reasonably possible that the estimated amount of the potential loss may change in the near term. Skye Bioscience, Inc. vs Partner Re Ireland Insurance In February 2023, the Company brought a suit against the Company's D&O insurance carrier, Partner Re Ireland Insurance DAC ("Partner Re"), bringing claims for (a) breach of contract, (2) tortious breach of the implied covenant of good faith and fair dealing and (3) declaratory relief that Partner Re is obligated to reimburse the Company for the defense fees and costs incurred in defense of the Cunning Lawsuit and must indemnify the Company for any settlement or judgment in the Cunning Lawsuit (the "Partner Re Lawsuit"). The Company's allegations arise out of Partner Re's refusal to reimburse the Company for costs incurred by the Company in defending the Cunning Lawsuit. The case, entitled Skye Bioscience, Inc., v. Partner Re Ireland Insurance DAC , was filed in the United Stated District Court for the Central District of California. On December 3, 2024, the Company entered into a settlement agreement with Partner Re for $ 2,000,000 in exchange for a full and final release of any future claims. For the year ended December 31, 2024 the Company recognized the income from insurance recovery in its consolidated statements of operations. F-30 12. Segment Reporting The Company operates in one business segment, which includes the business of research and development activities related to developing medicine for obesity and metabolic diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. In addition to the significant expense categories included within consolidated net loss presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise research and development expenses which are presented to the Company's CODM for review: Year Ended December 31, 2024 2023 External clinical development expenses (1) SBI-100 $ 2,033,722 $ 3,427,631 nimacimab 10,883,885 113,575 Cost to acquire IPR&D asset — 21,215,214 Personnel related and stock-based compensation 3,995,558 1,811,138 Other research and development expenses (2) 1,788,529 467,117 Total research and development expenses $ 18,701,694 $ 27,034,675 (1) External clinical development expenses include expenses for clinical trial costs and clinical manufacturing, as well as costs for discovery in research and development studies. (2) Other research and development expenses include expenses for travel and entertainment, consulting and advisory and general business expenses. The amount of property and equipment in the US was equal to $ 144,006 , and $ 134,554 for December 31, 2024 and December 31, 2023 , respectively. The amount of property and equipment outside of the US was equal to $ 1,522,258 , and $ 4,156 for December 31, 2024 and December 31, 2023 , respectively. 13 Subsequent Events Stock Option Grants Subsequent to December 31, 2024, the Company granted an aggregate of 1,160,000 and 56,000 common stock options to members of management, employees and directors under the Amended and Restated Plan and Inducement Plan, respectively . F-31 The following exhibits are filed with this Annual Report on Form 10-K. Exhibit Number Description of Exhibit 2.1 Arrangement Agreement, dated May 11, 2022, by and between the Company and EHT (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on May 11, 2022) 2.2 Amendment No. 1 to the Arrangement Agreement, dated June 14, 2022, by and between the Company and EHT (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on June 17, 2022) 2.3 Amendment No. 2 to the Arrangement Agreement, dated July 15, 2022, by and between the Company and EHT (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on July 21, 2022) 2.4 Amendment No. 3 to the Arrangement Agreement, dated October 18, 2022, by and between the Company and EHT (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 19, 2022) 2.6 Share Purchase Agreement, dated November 8, 2022, by and between Emerald Health Therapeutics, Inc., 14428773 Canada Inc., Verdelite Sciences, Inc., Verdelite Property Holdings, Inc. and C3 Centre Holding Inc. (incorporated by reference to Exhibit 10.3 to our Quarterly Report on Form 10-Q filed on November 14, 2022) 2.7 Amendment No. 1 to the Share Purchase Agreement, dated January 26, 2023, by and between Emerald Health Therapeutics, Inc., 14428773 Canada Inc., Verdelite Sciences, Inc., Verdelite Property Holdings, Inc. and C3 Centre Holding Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 27, 2023) 2.8 Amendment No. 2 to the Share Purchase Agreement, dated February 9, 2023, by and between Emerald Health Therapeutics, Inc., 14428773 Canada Inc., Verdelite Sciences, Inc., Verdelite Property Holdings, Inc. and C3 Centre Holding Inc. (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on February 15, 2023) 2.9 Agreement and Plan of Merger and Reorganization, dated August 15, 2023, by and among Skye Bioscience, Inc., Aquila Merger Sub, Inc., and Bird Rock Bio, Inc. ( incorporated by reference to Exhibit 2.9 to o ur Annua l Report on Form 10-K filed on March 22, 2024) 3.1 Articles of Incorporation of Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 22, 2024) 3.2 Amended and Restated Bylaws of Registrant (incorporated by reference to Exhibit 3.2 to our Report on Form 10-K filed on March 2, 2021) 4.1 Pre 2015 Common Stock Warrants (incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on November 3, 2014) 4.2 2015, 2016 and 2017 Form of Common Stock Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed August 20, 2015) 4.4 2019 Common Stock Warrants (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 21, 2019) 4.5 2020 Common Stock Warrants (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on August 5, 2020) 4.6 2021 Inducement Warrants (incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed November 10, 2021) 4.7 2021 Common Stock Warrants (incorporated by reference to Exhibit 4.1 to our Quarterly Report on Form 10-Q filed November 10, 2021) 4.8 2021 Pre-Funded Warrants (incorporated by reference to Exhibit 4.2 to our Quarterly Report on Form 10-Q filed November 10, 2021) 4.9 2021 Common Stock Warrants to Placement Agent (incorporated by reference to Exhibit 4.3 to our Quarterly Report on Form 10-Q filed November 10, 2021) 4.10 2022 Form of Warrant Issued to Former EHT Warrant Holders (incorporated by reference to Exhibit 4.12 to our Annual Report on Form 10-K filed on March 31, 2023) 4.11 2023 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on August 21, 2023) 4.12 2023 Common Stock Purchase Warrant issued by Skye Bioscience, Inc. to MFDI, LLC (incorporated by reference to Exhibit 4.3 to our Current Report on Form 8-K filed on August 21, 2023) 80 4.13 Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on January 29, 2024) 4.14 Amendment to Common Stock Purchase Warrants (incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 13, 2024) 4.15# Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 10.1†# Skye Bioscience, Inc. Amended and Restated Omnibus Incentive Plan and form of stock option agreements and form of restricted stock agreements thereunder 10.2†# Skye Bioscience, Inc. Amended and Restated 2024 Inducement Equity Incentive Plan and form of stock option agreement and form of restricted stock agreement thereunder 10.3† Skye Bioscience, Inc. 2022 Employee Stock Purchase Plan (incorporated by reference to Appendix C to our definitive proxy statement filed on August 31, 2022) 10.4† Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on January 12, 2015) 10.5† Form of Indemnification Agreement (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed on August 21, 2023) 10.6† Employment Agreement, dated August 10, 2020, by and between Skye Bioscience, Inc. and Punit Dhillon (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on August 12, 2020) 10.7† Employment Agreement, dated October 4, 2021, by and between Skye Bioscience, Inc. and Kaitlyn Arsenault (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on October 6, 2021) 10.8† A mendment to Executive Employment Agreement, dated May 11, 2023, by and between Skye Bioscience, Inc. and Kaitlyn Arsenault (incorporated by reference to Exhibit 10.5 to our Quarterly Report on Form 10-Q filed on May 12, 2023) 10.9† Employment Agreement, dated August 30, 2024, by and between Skye Bioscience, Inc. and Puneet Arora (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on September 4, 2024 ) 10.10†# Employment Agreement, dated October 5, 2020 , by and between Skye Bioscience, Inc. and Tu Diep 10.11†# Employment Agreement, dated November 11 , 2022 by and between Skye Bioscience, Inc. and Chris Twitty 10.12** Securities Purchase Agreement, dated as of August 15, 2023, by and among Skye Bioscience, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on August 21, 2023) 10.13** Registration Rights Agreement, dated as of August 15, 2023, by and among Skye Bioscience, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on August 21, 2023) 10.14** Secured Note and Warrant Purchase Agreement, dated as of August 15, 2023, by and among Skye Bioscience, Inc. and MFDI, LLC (incorporated by reference to Exhibit 10. 3 to our Current Report on Form 8-K filed on August 21, 2023) 10.15** Form of Securities Purchase Agreement, dated as of January 29, 2024, by and among Skye Bioscience, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.1 to our Quarterly Report on Form 10-Q filed on May 10, 2024 ) 10.16** Form of Securities Purchase Agreement, dated as of March 11, 2024, by and among Skye Bioscience, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed on March 13, 2024) 10.17** Form of Registration Rights Agreement, dated as of March 11, 2024, by and among Skye Bioscience, Inc. and the Investors named therein (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed on March 13, 2024) 10.18 Equity Distribution Agreement, dated as of May 10, 2024, by and between Skye Bioscience, Inc. and Piper Sandler & Co. (incorporated by reference to Exhibit 1.2 to our Registration Statement on Form S-3 filed on May 10, 2024) 10.19 Office Lease, dated as of August 25, 2021, by and between ROIC California, LLC and the Company (incorporated by reference to Exhibit 99.1 to our Current Report on Form 8-K filed on September 15, 2021) 81 19# Skye Bioscience, Inc. Insider Trading Policy 21.1# Subsidiaries of the Registrant 23.1# Consent of Marcum LLP 31.1# Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 31.2# Certification of Principal Financial and Accounting Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934 32.1# Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2# Certification of Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 97.1† Policy relating to recovery of erroneously awarded compensation, as required by applicable listing standards adopted pursuant to 17 CFR 240.10D-1 (incorporated by reference to Exhibit 97.1 to our Annual Report on Form 10-K filed on March 22, 2024) 101# Inline XBRL Document Set for the consolidated financial statements and accompanying notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) _________ # Filed Herewith ** Portions of this exhibit have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv). † Management contract or compensatory plan or arrangement. Item 16. Form 10-K Summary . None. 82 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Skye Bioscience, Inc. a Nevada corporation March 20, 2025 By: /s/ Punit Dhillon Punit Dhillon Its: Director, Chief Executive Officer (Principal Executive Officer) March 20, 2025 By: /s/ Kaitlyn Arsenault Kaitlyn Arsenault Its: Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 83 By: /s/ Punit Dhillon March 20, 2025 Punit Dhillon Its: Director, Chief Executive Officer (Principal Executive Officer) By: /s/ Kaitlyn Arsenault March 20, 2025 Kaitlyn Arsenault Its: Chief Financial Officer (Principal Financial and Accounting Officer) By: /s/ Paul Grayson March 20, 2025 Paul Grayson Its: Director, Chairman By: /s/ Deborah Charych March 20, 2025 Deborah Charych Its: Director By: /s/ Andrew J. Schwab March 20, 2025 Andrew J. Schwab Its: Director By: /s/ Karen Smith March 20, 2025 Karen Smith Its: Director By: /s/ Annalisa Jenkins March 20, 2025 Annalisa Jenkins Its: Director 84